Clearstone Reporting HbA1c Result Values in IFCC and NGSP Units for All Clinical Trials Globally
Clearstone Central Laboratories announced the company is reporting HbA1c result values in International Federation of Clinical Chemistry (IFCC) units as well as the National Glycohemoglobin Standardization Program (NGSP) standard units.
“Worldwide, many countries including most European countries, Japan and Australia have decided to change to IFCC units with a transition period of dual reporting” said Patrice Hugo, PhD, Clearstone’s Chief Scientific Officer. “We have been watching this issue very closely to advise our clients, and are pleased to offer the availability of both measurements for all studies through APOLLO CLPM™, our proprietary central laboratory protocol management system”.
As a result of having two reference standards for the measurement of HbA1c, Clearstone has made both reporting formats available to clients: IFCC (mmol/mol) and derived NGSP units (%). The correlation between these two is well documented, has been stable and is described by a robust equation: IFCC = (10.93 x NGSP) - 23.50. With this IFCC/NGSP master equation, all laboratories can provide derived units in either format. As recommended by the American Diabetes Association (ADA), Clearstone will continue to use an HbA1c threshold of 6.4% (46 mmol/mol) as the upper limit of normal.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
